DGPPN 2018 Programm

POSTER PRESENTATIONS 313 WEDNESDAY THURSDAY FRIDAY SATURDAY 011 Amygdala-vmPFC contributions to appetitive Pavlovian reinstatement in humans Claudia Ebrahimi, Berlin (Germany) Stefan Koch, Charlotte Pietrock, Thomas Fydrich, Andreas Heinz, Florian Schlagenhauf 012 Pupillary responses reflect condi- tioned value during appetitive Pavlovian learning Charlotte Pietrock, Berlin (Germany) Claudia Ebrahimi, Marcus Rothkirch, Teresa Katthagen, Stefan Koch, Andreas Heinz, Florian Schlagenhauf 013 Impact of CLU on white matter micro- structure in cognitively healthy elders – a diffusion tensor imaging (DTI) study Fabian Fußer, Frankfurt am Main (Germany) Kristin Weineck, Silke Matura, David Prvulovic, Johannes Klein, Andreas Reif, Johannes Pantel, Tarik Karakaya 014 The effect of ketamine infusion on interoceptive accuracy in healthy adults Zümrüt Duygu Sen, Tübingen (Germany) Julia Scheer, Lena Vera Danyeli, Lejla Colic, Martin Walter P-30 (e) Poster Presentation 13:30– 15:00 h | Hall Helsinki 1 /2 TOPIC 17: Pharmacotherapy Pharmacotherapy Chair: Ekkehard Haen, Regensburg (Germany) 001 Effects of St. John's wort, mique- lianin and hyperforin on CRH induced HPA axis activation in pituitary-derived AtT-20 cells Christiane Kolb, Darmstadt (Germany) Barbara Hochstrasser, Sarah Fankhauser, Heba Aziz-Kalbhenn, Veronika Butterweck 002 STW 3-VI (St. John's wort) increases plasticity of hippocampal neurons, as well as the migration of microglia cells and inhibits oxLDL-induced ROS production Olga Mierau, Marburg (Germany) Johanna Hofmann, Heba Aziz-Kalbhenn, Anna Schwendler, Gabriel A. Bonaterra, Ralf Kinscherf, Christiane Kolb 003 Benperidol – IV administration and QTc prolongation Joachim Scharfetter, Vienna (Austria) Peter Fischer, Beate Wally, Alexander Schmidt 004 Randomized, double-blind study of flexibly-dosed intranasal esketamine plus oral antidepressant vs. active control in treatment-resistant depression Vanina Popova, Beerse (Belgium) Ella Daly, Madhukar Trivedi, Kimberly Cooper, Rosanne Lane, Pilar Lim, Christine Mazzucco, David Hough, Michael E. Thase, Richard C. Shelton, Patricio Molero, Eduard Vieta, Malek Bajbouj, Husseini Manji, Wayne C. Drevets, Jaskaran B. Singh 005 Esketamine nasal spray combined with an oral antidepressant for relapse prevention in treatment-resistant depression: results of a double-blind, randomized withdrawal, multicenter study (SUSTAIN-1) Adam Janik, San Diego (USA) Ella Daly, Madhukar Trivedi, Honglan Li, Yun Zhang, Xiang Li, Rosanne Lane, Pilar Lim, Anna Duca, David Hough, Michael E. Thase, John M. Zajecka, Andrew Winokur, Ilona Divacka, Andrea Fagiolini, Wieslaw J. Cubala, Istvan Bitter, Pierre Blier, Richard C. Shelton, Patricio Molero, Husseini Manji, Wayne C. Drevets, Jaskaran B. Singh 006 Switching strategies for vortioxetine in the PREDDICT Study Bernhard T. Baune, Adelaide (Australia) Natalie Mills, Natalie Aboustate, Celia Fourier 007 Effect of carbamazepine on liver functionality Muhammed Touray, Kanifing (Gambia) 008 Optimization of pharmacological treatment in hospitalized psychiatric patients (OSA-PSY) Gudrun Hefner, Friedrichsdorf (Germany) Martina Hahn, Sibylle C. Roll, Christoph Hiemke, Ansgar Klimke 009 Antidepressants vs. antipsychotics in the treatment of patients with high- risk for psychosis Laura von Hardenberg, Berlin (Germany) Christoph U. Correll, Britta Galling